Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are major global health concerns, characterized by rising prevalence, high healthcare costs, and significant reductions in patients’ quality of life. Emerging evidence suggests that individuals with T2DM have nearly double the risk of developing AD, potentially due to overlapping mechanisms such as insulin resistance, oxidative stress, and neuroinflammation.
Objective
This study aims to systematically explore the evolving research landscape at the intersection of T2DM and AD over the past two decades, identifying major contributors, shifting research focuses, and emerging trends to inform future investigations and therapeutic development.
Methods
A comprehensive bibliometric analysis was conducted using data retrieved from the Web of Science Core Collection (WoSCC) spanning 2000 to 2024. A total of 3087 publications were analyzed using CiteSpace and the R package bibliometrix to assess publication trends, collaborative networks, and thematic evolution.
Results
The number of publications has steadily increased, with the United States and China emerging as dominant contributors. Institutions such as the University of California and Harvard University led in productivity and influence. Early research emphasized broad risk factors and cardiovascular comorbidities, while recent studies have shifted toward molecular mechanisms, particularly insulin resistance, neurodegeneration, and oxidative stress.
Conclusions
This 24-year bibliometric overview reveals a dynamic and expanding research field linking T2DM and AD. The findings highlight key geographic and institutional contributors, evolving thematic foci, and knowledge gaps, offering a valuable foundation for future research and potential therapeutic innovations.
2024 Alzheimer's disease facts and figures. Alzheimers Dement2024; 20: 3708–3821.
2.
JansonJLaedtkeTParisiJE, et al.Increased risk of type 2 diabetes in Alzheimer disease. Diabetes2004; 53: 474–481.
3.
OttAStolkRPvan HarskampF, et al.Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology1999; 53: 1937–1942.
4.
ArvanitakisZWilsonRSBieniasJL, et al.Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol2004; 61: 661–666.
5.
HuangCCChungCMLeuHB, et al.Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLoS One2014; 9: e87095.
6.
LiWTiedtSLoEH. Tau in the pancreas: understanding the link between type 2 diabetes mellitus and Alzheimer's disease. Signal Transduct Target Ther2023; 8: 447.
7.
StanciuGDBildVAbabeiDC, et al.Link between diabetes and Alzheimer's disease due to the shared amyloid aggregation and deposition involving both neurodegenerative changes and neurovascular damages. J Clin Med2020; 9: 1713.
8.
VieiraMNNLima-FilhoRASFeliceD,et al.Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets. Neuropharmacology2018; 136: 160–171.
9.
ZhangJChenCHuaS, et al.An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer's disease. Diabetes Res Clin Pract2017; 124: 41–47.
10.
HaiYRenKZhangY, et al.HIF-1α serves as a co-linker between AD and T2DM. Biomed Pharmacother2024; 171: 116158.
11.
HaqueRNazirA. Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets2014; 13: 259–264.
12.
MaciejczykMŻebrowskaEChabowskiA. Insulin resistance and oxidative stress in the brain: what's new?Int J Mol Sci2019; 20: 874.
13.
WangYHuHLiuX, et al.Hypoglycemic medicines in the treatment of Alzheimer's disease: pathophysiological links between AD and glucose metabolism. Front Pharmacol2023; 14: 1138499.
14.
XuXSunYCenX, et al.Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model. Protein Cell2021; 12: 769–787.
15.
CummingsJOrtizACastellinoJ, et al.Diabetes: risk factor and translational therapeutic implications for Alzheimer's disease. Eur J Neurosci2022; 56: 5727–5757.
PengYYaoSYChenQ, et al.True or false? Alzheimer's disease is type 3 diabetes: evidences from bench to bedside. Ageing Res Rev2024; 99: 102383.
18.
de la MonteSMTongM. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol2014; 88: 548–559.
19.
FernandezAMTorres-AlemánI. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci2012; 13: 225–239.
20.
BelliaCLombardoMMeloniM, et al.Diabetes and cognitive decline. Adv Clin Chem2022; 108: 37–71.
21.
BiesselsGJDespaF. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol2018; 14: 591–604.
22.
QinYFRenSHShaoB, et al.The intellectual base and research fronts of IL-37: a bibliometric review of the literature from WoSCC. Front Immunol2022; 13: 931783.
23.
LiDYuDLiY, et al.A bibliometric analysis of PROTAC from 2001 to 2021. Eur J Med Chem2022; 244: 114838.
24.
ScaranoAAriaMMaurielloF, et al.Systematic literature review of 10 years of cyclist safety research. Accid Anal Prev2023; 184: 106996.
25.
SongLZhangJMaD, et al.A bibliometric and knowledge-map analysis of macrophage polarization in atherosclerosis from 2001 to 2021. Front Immunol2022; 13: 910444.
26.
WangLFengWDuanJ, et al.Pharmacovigilance bibliometrics: visualizing thematic development in the category of pharmacology and pharmacy in web of science. Front Pharmacol2021; 12: 731757.
27.
ChenC. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A2004; 101: 5303–5310.
28.
CuccurulloAMbibliometrixC. An R-tool for comprehensive science mapping analysis. J Informetr2017; 11: 959–975.
29.
FrancoPDe FeliceFKaidar-PersonO, et al.Equity, diversity, and inclusion in radiation oncology: a bibliometric analysis and critical review. Int J Radiat Oncol Biol Phys2023; 116: 232–245.
30.
ArnoldSEArvanitakisZMacauley-RambachSL, et al.Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol2018; 14: 168–181.
31.
TalbotKWangHYKaziH, et al.Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest2012; 122: 1316–1338.
32.
LiBXuZ. Insights into financial technology (FinTech): a bibliometric and visual study. Financ Innov2021; 7: 69.
33.
LiYFangRLiuZ, et al.The association between toxic pesticide environmental exposure and Alzheimer's disease: a scientometric and visualization analysis. Chemosphere2021; 263: 128238.
34.
WangJWangXCaiX, et al.Global trends and hotspots in IgA nephropathy: a bibliometric analysis and knowledge map visualization from 2012 to 2023. Int Urol Nephrol2023; 55: 3197–3207.
35.
AndrásSGáborS. Lawmaker “pioneers” of scientometrics. Orv Hetil2016; 157: 74–78.
36.
MantikKEKKimSGuB, et al.Repositioning of anti-diabetic drugs against dementia: insight from molecular perspectives to clinical trials. Int J Mol Sci2023; 24: 11450.
37.
ShenZLiZYYuMT, et al.Metabolic perspective of astrocyte dysfunction in Alzheimer's disease and type 2 diabetes brains. Biomed Pharmacother2023; 158: 114206.
38.
McCleanPLParthsarathyVFaivreE, et al.The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci2011; 31: 6587–6594.
39.
ChauhanADubeySJainS. Association between type 2 diabetes mellitus and Alzheimer's disease: common molecular mechanism and therapeutic targets. Cell Biochem Funct2024; 42: e4111.
40.
SteenETerryBMRiveraEJ, et al.Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes?J Alzheimers Dis2005; 7: 63–80.
41.
BiesselsGJStaekenborgSBrunnerE, et al.Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol2006; 5: 64–74.
42.
CranePKWalkerRHubbardRA, et al.Glucose levels and risk of dementia. N Engl J Med2013; 369: 540–548.
43.
MoranCBeareRPhanTG, et al.Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology2015; 85: 1123–1130.
44.
TakedaSSatoNUchio-YamadaK, et al.Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A2010; 107: 7036–7041.
45.
CraftSBakerLDMontineTJ, et al.Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol2012; 69: 29–38.
46.
De FeliceFGVieiraMNBomfimTR, et al.Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A2009; 106: 1971–1976.
47.
BomfimTRForny-GermanoLSathlerLB, et al.An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest2012; 122: 1339–1353.
48.
GejlMGjeddeAEgefjordL, et al.In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci2016; 8: 108.
49.
MoloneyAMGriffinRJTimmonsS, et al.Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging2010; 31: 224–243.
50.
KandimallaRThirumalaVReddyPH. Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis2017; 1863: 1078–1089.
51.
De FeliceFGSTF. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes2014; 63: 2262–2272.
52.
KellarDCraftS. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol2020; 19: 758–766.
53.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2020; 396: 413–446.
54.
MichailidisMMoraitouDTataDA, et al.Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes. Int J Mol Sci2022; 23: 2687.
55.
AnYVarmaVRVarmaS, et al.Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimers Dement2018; 14: 318–329.
56.
ShiuchiTIwaiMLiHS, et al.Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension2004; 43: 1003–1010.
57.
JohnsonECBBianSHaqueRU, et al.Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease. Nat Med2023; 29: 1979–1988.
58.
FarrisWMansourianSChangY, et al.Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A2003; 100: 4162–4167.
59.
VekrellisKYeZQiuWQ, et al.Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci2000; 20: 1657–1665.
60.
YangYSongW. Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience2013; 250: 140–150.
61.
ColeGMFrautschySA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp Gerontol2007; 42: 10–21.
62.
BenedictCGrilloCA. Insulin resistance as a therapeutic target in the treatment of Alzheimer's disease: a state-of-the-art review. Front Neurosci2018; 12: 215.
63.
LiXSongDLengSX. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin Interv Aging2015; 10: 549–560.
64.
LittleKLlorián-SalvadorMScullionS, et al.Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends Endocrinol Metab2022; 33: 50–71.
65.
PugazhenthiSQinLReddyPH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis2017; 1863: 1037–1045.
66.
ShiikiTOhtsukiSKuriharaA, et al.Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci2004; 24: 9632–9637.
67.
LiLHolscherC. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev2007; 56: 384–402.
68.
LyPTWuYZouH, et al.Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest2013; 123: 224–235.
69.
PhielCJWilsonCALeeVM, et al.GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature2003; 423: 435–439.
70.
VingtdeuxVHamdaneMGompelM, et al.Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis2005; 20: 625–637.
71.
GabboujSRyhänenSMarttinenM, et al.Altered insulin signaling in Alzheimer's disease brain - special emphasis on PI3K-Akt pathway. Front Neurosci2019; 13: 629.
72.
SchubertMGautamDSurjoD, et al.Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A2004; 101: 3100–3105.
73.
ShiJZhangTZhouC, et al.Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in down syndrome. J Biol Chem2008; 283: 28660–28669.
74.
YinXJinNShiJ, et al.Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn down syndrome mice. Sci Rep2017; 7: 619.
75.
EikelenboomPvan ExelEHoozemansJJM, et al.Neuroinflammation – an early event in both the history and pathogenesis of Alzheimer’s disease. Neurodegener Dis2010; 7: 38–41.
76.
MarkesberyWRCarneyJM. Oxidative alterations in Alzheimer's disease. Brain Pathol1999; 9: 133–146.
77.
BlaskoIStampfer-KountchevMRobatscherP, et al.How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell2004; 3: 169–176.
78.
CanteiroPBAnteroDCTramontinNDS, et al.Insulin treatment protects the brain against neuroinflammation by reducing cerebral cytokines and modulating mitochondrial function. Brain Res Bull2019; 149: 120–128.
79.
de la MonteSM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs2012; 72: 49–66.
80.
Lester-CollNRiveraEJSosciaSJ, et al.Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis2006; 9: 13–33.
81.
Baglietto-VargasDShiJYaegerDM, et al.Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev2016; 64: 272–287.
82.
FerreiraLSSFernandesCSVieiraMNN, et al.Insulin resistance in Alzheimer's disease. Front Neurosci2018; 12: 830.
83.
MilsteinJLFerrisHA. The brain as an insulin-sensitive metabolic organ. Mol Metab2021; 52: 101234.
84.
SalasIHDe StrooperB. Diabetes and Alzheimer's disease: a link not as simple as it seems. Neurochem Res2019; 44: 1271–1278.
85.
McEwenBSReaganLP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol2004; 490: 13–24.
86.
SankarRThamotharanSShinD, et al.Insulin-responsive glucose transporters-GLUT8 and GLUT4 are expressed in the developing mammalian brain. Brain Res Mol Brain Res2002; 107: 157–165.
87.
SpinelliMFuscoSGrassiC. Brain insulin resistance and hippocampal plasticity: mechanisms and biomarkers of cognitive decline. Front Neurosci2019; 13: 788.
88.
BlázquezEHurtado-CarneiroVLeBaut-AyusoY, et al.Significance of brain glucose hypometabolism, altered insulin signal transduction, and insulin resistance in several neurological diseases. Front Endocrinol (Lausanne)2022; 13: 873301.
89.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 280–292.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
